SCHEMBL1241066

SCHEMBL1241066

O=C1CCCOc2cc3c(cc21)OCO3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
MAPT P10636 5/20 0.42
KDM4E B2RXH2 3/20 0.41
ACHE P22303 1/20 0.41
GRIA1 P42261 1/20 0.39
SMN1; SMN2 Q16637 6/20 0.38
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 2/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALOX12 P18054 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EP300 Q09472 1/20 0.37
CYP2D6 P10635 1/20 0.37
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL86325 0.89 MAOB (0.53) MAOAMAOBKDM4EACHEGRIA1
SCHEMBL20165210 0.78 MAOB (0.42) MAOAMAOBACHEGRIA1SMN1; SMN2
SCHEMBL913765 0.78 MAOB (0.42) MAOAMAOBSMN1; SMN2RAB9AALDH1A1
SCHEMBL10334865 0.78 IMPDH2 (0.42) MAOAMAOBKDM4ESMN1; SMN2RAB9A
SCHEMBL12341987 0.78 KDM4E (0.50) MAOAMAOBMAPTKDM4EACHE
SCHEMBL86805 0.78 MAOB (0.62) MAOAMAOBSMN1; SMN2RAB9AALDH1A1
SCHEMBL86420 0.76 ACHE (0.46) MAOAMAOBMAPTKDM4EACHE
SCHEMBL1243316 0.76 KDM4E (0.54) MAOAMAOBMAPTKDM4EACHE
SCHEMBL1243457 0.76 KDM4E (0.54) MAOAMAOBMAPTKDM4EACHE
SCHEMBL10334869 0.74 KDM4E (0.45) MAOAMAOBMAPTKDM4EACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders THE JOHNS HOPKINS UNIVERSITY (US) 2019-11-12 US disclosed
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2012-08-02 US disclosed
WO-2011017519-A2 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196852-A1 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS METAP1, METAP2, ENPEP MAOA 356/4885MAOB 213/4885MAPT 1551/4885
US-10472315-B2 Inhibitors of methionine aminopeptidases and methods of treating disorders METAP1, METAP2, ENPEP MAOA 356/4885MAOB 213/4885MAPT 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.